In recent trading session, Chembio Diagnostics, Inc. (NASDAQ:CEMI) saw 3,125,328 shares changing hands at last check today with its beta currently measuring 2.06. Company’s recent per share price level of $6.32 trading at $0.93 or 17.16% at last check today assigns it a market valuation of $126.28 Million. That most recent trading price of CEMI’s stock is at a discount of -151.42% from its 52-week high price of $15.89 and is indicating a premium of 64.4% from its 52-week low price of $2.25. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 797.99 Million shares which gives us an average trading volume of 1.53 Million if we extend that period to 3-months.
For Chembio Diagnostics, Inc. (CEMI), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2. Splitting up the data highlights that, out of 3 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.28 in the current quarter.
Chembio Diagnostics, Inc. (NASDAQ:CEMI) trade information
Upright in the green today for gaining 17.16%, in the last five days CEMI remained trading in the green while hitting it’s week-highest on Thursday, Jan 14 when the stock touched $6.59-2 price level, adding 2.44% to its value on the day. Chembio Diagnostics, Inc.’s shares saw a change of 35.35% in year-to-date performance and have moved 27.82% in past 5-day. Chembio Diagnostics, Inc. (NASDAQ:CEMI) showed a performance of 15.63% in past 30-days. Number of shares sold short was 3.8 Million shares which calculate 2.48 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $9 to the stock, which implies a rise of 42.41% to its recent value today. Analysts have been projecting $8 as a low price target for the stock while placing it at a high target of $10. It follows that stock’s price at last check today has to jump +58.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of 26.58% for stock’s latest value.
Chembio Diagnostics, Inc. (CEMI) estimates and forecasts
Statistics highlight that Chembio Diagnostics, Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added +5.69% of value to its shares in past 6 months. Apart from that, the company came lowering its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to decline by -16.7% in the current quarter and calculating 17.2% increase in the next quarter. This year revenue growth is estimated to drop -18.7% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $5.77 Million for the same. And 2 analysts are in estimates of company making revenue of $6.43 Million in the next quarter that will end on March 01, 2021. Company posted $6.85 Million and $6.86 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -15.8% while estimating it to be -6.3% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.6% during past 5 years. In 2021, company’s earnings growth rate is likely to be around -48% while estimates for its earnings growth in next 5 years are of 25%
Chembio Diagnostics, Inc. (NASDAQ:CEMI)’s Major holders
Insiders are in possession of 13.89% of company’s total shares while institution are holding 33.75% percent of that, with stock having share float percentage of 39.19%. Investors also watch the number of corporate investors in a company very closely, which is 91 institutions for Chembio Diagnostics, Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at CEMI for having 1.31 Million shares of worth $6.35 Million. And as of September 29, 2020, it was holding 6.47% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 1.17 Million shares on September 29, 2020. The number of shares represents firm’s hold over 5.8% of outstanding shares, having a total worth of $5.68 Million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of September 29, 2020, the former fund manager was holding 542939 shares of worth $2.64 Million or 2.69% of the total outstanding shares. The later fund manager was in possession of 434.94 Thousand shares on December 30, 2020, making its stake of worth around $2.07 Million in the company or a holder of 2.16% of company’s stock.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.